Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

B cell receptor dependent infection as a mechanism of immune-mediated enhancement of dengue virus infection and pathogenesis

Award Number: R01AI192874
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/07/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2030

Group Awards By:

View Award Description

B cell receptor dependent infection as a mechanism of immune-mediated enhancement of dengue virus infection and pathogenesis - Four serotypes of dengue virus (DENV1-4) cause 100 million symptomatic dengue cases annually. While the majority of DENV infections resolve without the need for medical intervention, dengue can quickly progress in some patients to potentially fatal dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). The risk factors associated with progressing to severe dengue are complex and incompletely understood. However, the risk of developing severe disease increases significantly in individuals experiencing secondary/heterologous infections. The leading mechanistic explanation for this phenomenon is Antibody-Dependent Enhancement (ADE), wherein DENV-specific IgG antibodies elicited by a prior heterotypic DENV infection opsonize DENV without neutralizing infectivity, facilitating uptake by FcγR-bearing phagocytes such as monocytes and macrophages. However, analysis of samples from individuals experiencing acute DENV infection reveals that B cells are the largest reservoir of infected circulating cells, representing a disconnect in our understanding of immune-mediated DENV tropism. While B cells are known to be phagocytic, their antigen-specific receptors provide an additional means of internalizing extracellular antigens. Our team has recently demonstrated that the expression of a DENV-specific B cell receptor (BCR) renders cells highly susceptible to DENV infection. In addition, we have demonstrated that the frequency of DENV-infectable B cell is influenced by flavivirus immune status, with the frequency of DENV-infectible B cells increasing significant in previously flavivirus-naïve individuals after a primary DENV infection. We posit a new paradigm where cross-reactive non-neutralizing antibodies, when expressed in their transmembrane form as B cell receptors (BCR) on DENV-specific B cells are capable of mediating BCR-dependent enhancement (BDE) DENV infection, replication, and immunopathogenesis. Our long-term goal is to understand how B cells themselves alongside their antibody products can contribute to protection from or susceptibility to DENV infection and disease. Accordingly, our objective with this submission is to define the mechanistic requirements underpinning the process of BDE and to understand how risk of BDE is modulated by DENV infection and/or vaccination.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $649,530 )
2025	2025	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	750 E ADAMS ST	SYRACUSE	NY	13210	ONONDAGA	USA	Allergy and Infectious Diseases Research	000	1	7/7/2025	NEW	$649,530
														Subtotal = $649,530

Grand Total All Awards = $649,530

Top

All Categories

About

Search

Reports

Data Submission

Award Information

B cell receptor dependent infection as a mechanism of immune-mediated enhancement of dengue virus infection and pathogenesis

Award Number: R01AI192874

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/07/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer